Disclosure Information

I hereby declare that I have had business or personal interests in the following industrial enterprises since 1 September 2016:

Name of the enterprise / Nature of the interest

<table>
<thead>
<tr>
<th>Enterprise</th>
<th>Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017</td>
<td></td>
</tr>
<tr>
<td>Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017</td>
<td></td>
</tr>
</tbody>
</table>
ESP Working Group Uropathology BM 2017

- www.esp-pathology.org
- Members WG: Web registry
- ECP Bilbao 2017
- SYM: Prostate & Kidney
- BM: Advances in URO
- VM: Secondary Tumors in Uropathology
- Join GYN-URO: Dysplasia/In Situ
Milan Uropathology Course

KIDNEY TUTORIAL COURSE

THE CHALLENGING ERA OF IMMUNOTHERAPY

Director

Nevio Colizzi

Ir. Urologia Chirurgia e Radiotherapy INPST-EMIC

Siciliano di Urologia e Radiotherapy INPST-EMIC

European Society of Pathology

ESchoP 2018
Bulgaria
Diagnostic Uropathology Course
Giordano Fellowship GU

- Germany: Prof Hartmann
- Czech Republic: Prof Hes
ESP Working Group Uropathology BM

- Members participation in scientific activities
- Ongoing project:
  - Genitourinary Neuroendocrine Tumors
  - Evaluation and reporting of Anti-PD-L1 immunohistochemistry
    - Recommendation-guide by WG
# BLADDER CANCER IMMUNOTHERAPY

<table>
<thead>
<tr>
<th></th>
<th>Durvalumab</th>
<th>Atezolizumab</th>
<th>Nivolumab</th>
<th>Pembrolizumab</th>
<th>Avelumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1 assay</td>
<td>Ventana SP263</td>
<td>Ventana SP142</td>
<td>Dako 28.8</td>
<td>Dako 22C3</td>
<td>Dako 73-10</td>
</tr>
<tr>
<td>(antibody)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell-types scored for UC</td>
<td>IC and TC</td>
<td>IC</td>
<td>TC</td>
<td>TC and IC</td>
<td>TC</td>
</tr>
<tr>
<td>PD-L1 cut offs: High/positive</td>
<td>≥25% TC or IC</td>
<td>≥5% IC</td>
<td>≥5% IC</td>
<td>≥1% TC</td>
<td>≥10% CPS</td>
</tr>
<tr>
<td>Low/negative</td>
<td>&lt;25% TC and IC</td>
<td>&lt;1% IC</td>
<td>&lt;1% IC</td>
<td>&lt;1% TC</td>
<td>&lt;10% CPS</td>
</tr>
<tr>
<td>Line of therapy</td>
<td>≥1L</td>
<td>≥2L</td>
<td>1L</td>
<td>≥2L</td>
<td>2L</td>
</tr>
</tbody>
</table>

ESP Working Group Uropathology BM

• ESP WG Uropathology (period 2016-2020)
• Chair: Dr Antonio Lopez-Beltran MD
• (em1lobea@gmail.com)
• Secretary: Dr Maurizio Colecchia
• (maurizio.colecchia@istitutotumori.mi.it)